Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hanwha Ocean (042660) – Correction of Decision on Capital Increase by Subsidiary / 2024-12-30

Posted on December 30, 2024August 8, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Capital Increase by Subsidiary / 2024-12-30

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Hanwha Ocean has filed a corrected disclosure updating the authorized share limit to 10,000 shares and changing the payment date to undecided (to be disclosed via amended filing once finalized) regarding the capital increase of its subsidiary (Hanwha Ocean USA Holdings Corp.).

📊 [Key Disclosure Details & Financial Highlights]

  • Correction Classification: Corrected Filing (Report)
  • Correction Filing Date: December 30, 2024
  • Original Disclosure Document & Date: Decision on Capital Increase by Subsidiary (June 14, 2024)
  • Reason for Correction: Change in payment date, revision of authorized share count
  • Major Corrected Items:
    • Share Price Determination Method (Authorized Share Limit): Determined within the limit of 5,000 authorized shares before correction → Determined within the limit of 10,000 authorized shares after correction
    • Payment Date: December 31, 2024, before correction → Undecided after correction (to be disclosed via amended filing once final completion date is fixed)
  • Subsidiary Details:
    • Subsidiary Name: Hanwha Ocean USA Holdings Corp. (CEO: Yeon-Seong Jang / Main Business: Maritime Service)
    • Major Subsidiary Status: N/A
  • Capital Increase Details:
    • Class and Number of New Shares: Common stock 2,650 shares
    • Par Value per Share: KRW 1,371 (1 USD / Exchange rate of KRW 1,371.00/USD as of June 14, 2024 applied)
    • Total Issued Shares Before Capital Increase: Common stock 1,352 shares
    • Use of Proceeds by Purpose:
      • Acquisition of Securities of Other Corporations: KRW 363,300,000,000 (approx. KRW 363.3B / USD 265,000,000)
    • Capital Increase Method: Capital Increase by Shareholder Allocation
    • Number of New Shares Allocated Per Share: 1.9600592 shares
    • Total Issue Amount for New Shares: KRW 363,300,000,000 (approx. KRW 363.3B)
    • Board Resolution Date: June 13, 2024 (US local time)
  • Other Important Notes:
    • Purpose is to secure investment capital for the 100%-owned subsidiary
    • Converted KRW amounts apply the exchange rate as of June 14, 2024 (1 USD = KRW 1,371.00) and may fluctuate based on exchange rates at actual execution
    • Exempt from Securities Registration Statement requirement as a foreign unlisted entity
    • Related Disclosure: June 14, 2024 (Decision on Capital Increase by Subsidiary)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Authorized Share Limit Revision and Subsequent Filings for Confirmed Payment Date

This correction filing notifies the market that the authorized share limit for the subsidiary’s capital increase was updated to 10,000 shares and that the payment date was changed to undecided, with a corrected disclosure scheduled once the final completion date is confirmed. Verifying whether a subsequent corrected disclosure is filed with the finalized payment date is essential for tracking the actual execution progress of the initially disclosed capital increase terms. Related details can be verified in upcoming official regular filings, including Quarterly, Half-Yearly, and Annual Reports.

📢 Disclaimer & Fact Source

Source: This content was structured and newly written based on officially submitted data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This material is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Shipbuilding

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Acquisition of Shares or Equity Securities of Other Corporations / 2024-12-30
Next Post: [Disclosure] Hanwha Ocean (042660) – Correction of Decision on Capital Increase by Subsidiary / 2024-12-30

Related Posts

[Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Korea (Correction) / 2026-04-24 Disclosures
[Disclosure] Daeduck Electronics (353200) – Corporate Value-Up Plan / 2026-03-27 Disclosures
[Disclosure] Samsung Electro-Mechanics (009150) – Consolidated Earnings Announcement (Provisional) / 2026-07-30 Disclosures
[Disclosure] Hanwha Aerospace (012450) – Q1 2024 Preliminary Consolidated Financial Results (Revenue KRW 1.848T / Operating Profit KRW 37.4B) Disclosures
[Disclosure] SK Hynix (000660) – Provisional Financial Results (Fair Disclosure) / 2024-04-25 Semiconductors
[Disclosure] ISU PETASYS (007660) – Submission of Audit Report / 2024-03-21 Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme